Urothelial Carcinoma Uc clinical trials

Explore recruiting urothelial carcinoma uc clinical trials.

Recruiting urothelial carcinoma uc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Urothelial Carcinoma Uc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies

Italy, Bulgaria, Poland, Romania, France, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma (MORPHEUS-UC)

France, Greece, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer

Germany, Greece, Denmark, France, Romania, Poland +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Selective Bladder-Sparing Trial with Sasanlimab as Maintenance Treatment Based On Clinical Response To Neoadjuvant Treatment In Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

Poland, Spain, Italy, Hungary

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

Poland, Spain, Germany, Italy, Austria, France +1 more

Human Pharmacology (Phase I)- Other EU CTIS Study details

Urothelial Carcinoma Uc trials by city

Urothelial Carcinoma Uc in Toronto Urothelial Carcinoma Uc in Vancouver Urothelial Carcinoma Uc in Montreal Urothelial Carcinoma Uc in Calgary Urothelial Carcinoma Uc in Edmonton Urothelial Carcinoma Uc in Ottawa Urothelial Carcinoma Uc in Winnipeg Urothelial Carcinoma Uc in Quebec City Urothelial Carcinoma Uc in Hamilton Urothelial Carcinoma Uc in Kitchener Urothelial Carcinoma Uc in London Urothelial Carcinoma Uc in Halifax Urothelial Carcinoma Uc in New York Urothelial Carcinoma Uc in Los Angeles Urothelial Carcinoma Uc in Chicago Urothelial Carcinoma Uc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease